Thus, evaluating the expressionof the miR-326 could be used as a biomarker for theassessment of the immune cell function in MS patients.Interferon-beta (IFN-ß) was the first disease-modifyingdrug used for the treatment of MS with long-lasting effectand well-tolerability (14). This evidence concerns the gene IFNA1 and myeloid sarcoma.